These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9833601)

  • 1. Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.
    Otto C; Parhofer KG; Ritter MM; Richter WO; Schwandt P
    Br J Clin Pharmacol; 1998 Nov; 46(5):473-8. PubMed ID: 9833601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia.
    Taskinen MR; Nikkilä EA
    Atherosclerosis; 1988 Feb; 69(2-3):249-55. PubMed ID: 3279968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.
    Koev D; Zlateva S; Susic M; Babic D; Profozic V; Skrabalo Z; Langrová H; Cvrkalová AL; Rajecová E; Klimes I
    Diabetes Care; 1993 Sep; 16(9):1285-90. PubMed ID: 8404433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term Acipimox decreases the ability of plasma from Type 2 diabetic patients and healthy subjects to stimulate cellular cholesterol efflux: a potentially adverse effect on reverse cholesterol transport.
    Dullaart RP; van Tol A
    Diabet Med; 2001 Jun; 18(6):509-13. PubMed ID: 11472472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.
    Stuyt PM; Stalenhoef AF; Demacker PN; Van 't Laar A
    Atherosclerosis; 1985 Apr; 55(1):51-62. PubMed ID: 3924065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of long-term pharmacological antilipolysis on substrate metabolism in growth hormone (GH)-substituted GH-deficient adults.
    Nielsen S; Møller N; Pedersen SB; Christiansen JS; Jørgensen JO
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3274-8. PubMed ID: 12107236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia.
    Ko GT; Mak TW; Yeung VT; Chan DC; Lam CW; Tsang LW; Chow CC; Cockram CS
    J Clin Pharmacol; 1998 Oct; 38(10):912-7. PubMed ID: 9807971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
    Series JJ; Gaw A; Kilday C; Bedford DK; Lorimer AR; Packard CJ; Shepherd J
    Br J Clin Pharmacol; 1990 Jul; 30(1):49-54. PubMed ID: 2390432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia.
    Dean JD; McCarthy S; Betteridge DJ; Whately-Smith C; Powell J; Owens DR
    Diabet Med; 1992; 9(7):611-5. PubMed ID: 1511566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acipimox attenuates hypertriglyceridemia in dyslipidemic noninsulin dependent diabetes mellitus patients without perturbation of insulin sensitivity and glycemic control.
    Shih KC; Kwok CF; Hwu CM; Hsiao LC; Li SH; Liu YF; Ho LT
    Diabetes Res Clin Pract; 1997 May; 36(2):113-9. PubMed ID: 9229195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.
    Hadigan C; Liebau J; Torriani M; Andersen R; Grinspoon S
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4438-44. PubMed ID: 16940448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1998 May; 243(5):151-6. PubMed ID: 9651568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood and plasma viscosity after acipimox treatment in hypertriglyceridemic patients.
    Montefusco S; Iannaci G; Gnasso A; Cortese C; Lamenza F; Postiglione A
    Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):492-4. PubMed ID: 3235215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover.
    Seed M; O'Connor B; Perombelon N; O'Donnell M; Reaveley D; Knight BL
    Atherosclerosis; 1993 Jun; 101(1):61-8. PubMed ID: 8216503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
    O'Kane MJ; Trinick TR; Tynan MB; Trimble ER; Nicholls DP
    Br J Clin Pharmacol; 1992 Apr; 33(4):451-3. PubMed ID: 1576071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cholestyramine and acipimox on subfractions of plasma low density lipoprotein. Studies in normolipidaemic and hypercholesterolaemic subjects.
    Griffin BA; Caslake MJ; Gaw A; Yip B; Packard CJ; Shepherd J
    Eur J Clin Invest; 1992 Jun; 22(6):383-90. PubMed ID: 1633833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.